Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 57 (1) , 282-292
- https://doi.org/10.1046/j.1523-1755.2000.00819.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Aluminum is a weak agonist for the calcium-sensing receptorKidney International, 1999
- Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidismKidney International, 1997
- Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failureAmerican Journal of Kidney Diseases, 1997
- Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.Journal of Clinical Investigation, 1995
- Oral versus intravenous calcitriolCurrent Opinion in Nephrology and Hypertension, 1995
- Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidismKidney International, 1993
- Oral Calcium Effectively Reduces Parathyroid Hormone Levels in Hemodialysis Patients: A Randomized Double-Blind Placebo-Controlled StudyNephron, 1993
- Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriolKidney International, 1991
- Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolismKidney International, 1989
- Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidismKidney International, 1988